{"denoms":[{"counts":[{"groupId":"BG000","value":"246"},{"groupId":"BG001","value":"487"},{"groupId":"BG002","value":"733"}],"units":"Participants"}],"groups":[{"description":"Participants received placebo matching niraparib 300 milligram (mg) (3×100 mg capsules) (fixed dose) once daily (QD) orally beginning on Day 1 of every cycle (each cycle of 28-days) in a double-blind fashion until a modified starting dose regimen was implemented in protocol amendment. After the protocol amendment, participants received placebo based upon the participant's Baseline body weight or Baseline platelet count (individualized dose): 300 mg (3×100 mg capsules for participants with a Baseline body weight \\>=77 kilogram \\[kg\\] and Baseline platelet count \\>=150,000 per microliter \\[μL\\]) or 200 mg (2×100 mg capsules for participants with a Baseline body weight \\<77 kg or Baseline platelet count \\<150,000 per μL).","id":"BG000","title":"Placebo"},{"description":"Participants received niraparib 300 mg (3×100 mg capsules) (fixed dose) QD orally beginning on Day 1 of every cycle (each cycle of 28-days) in a double-blind fashion until a modified starting dose regimen was implemented in protocol amendment. After the protocol amendment, participants received niraparib based upon the participant's Baseline body weight or Baseline platelet count (individualized dose): 300 mg (3×100 mg capsules for participants with a Baseline body weight \\>=77 kg and Baseline platelet count \\>=150,000 per μL) or 200 mg (2×100 mg capsules for participants with a Baseline body weight \\<77 kg or Baseline platelet count \\<150,000 per μL).","id":"BG001","title":"Niraparib"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"10.39","value":"61.3"},{"groupId":"BG001","spread":"10.79","value":"61.1"},{"groupId":"BG002","spread":"10.65","value":"61.2"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"246"},{"groupId":"BG001","value":"487"},{"groupId":"BG002","value":"733"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"219"},{"groupId":"BG001","value":"436"},{"groupId":"BG002","value":"655"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"12"}],"title":"Black"},{"measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"25"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}],"title":"Native Hawaiian or other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"25"},{"groupId":"BG002","value":"39"}],"title":"Unknown"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"}],"populationDescription":"Baseline characteristics were presented for all randomized participants including 5 randomized participants who never received treatment (4-Screen failure and 1-Withdrew consent)."}